Patents by Inventor Derek Cogan

Derek Cogan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HETEROCYCLIC INHIBITORS OF ENPP1
    Publication number: 20240376113
    Abstract: The present disclosure relates generally to inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), compositions thereof, and methods of using said compounds and compositions thereof. More specifically, the present disclosure relates to triazolopyrimidine and imidazolopyrimidine inhibitors of ENPP1 and methods of their use for treating disease mediated by ENPP1.
    Type: Application
    Filed: July 12, 2024
    Publication date: November 14, 2024
    Applicant: Volastra Therapeutics, Inc.
    Inventors: Sarah BETTIGOLE, Michael SU, Derek A. COGAN, Leon VAN BERKOM, Piotr NIECZYPOR, Gydo VAN DER HEIJDEN, Prashanna VIJAYACHANDRAN
  • INDOLINE COMPOUNDS FOR INHIBITING KIF18A
    Publication number: 20240351984
    Abstract: The present disclosure relates generally to inhibitors of KIF18A, compositions thereof, and methods of using said compounds and compositions thereof. More specifically, the present disclosure relates to indoline inhibitors of KIF18A and methods of their use for treating disease mediated by KIF18A, such as cancer.
    Type: Application
    Filed: June 5, 2024
    Publication date: October 24, 2024
    Applicant: Volastra Therapeutics, Inc.
    Inventor: Derek A. COGAN
  • Heterocyclic inhibitors of ENPP1
    Patent number: 12091412
    Abstract: The present disclosure relates generally to inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), compositions thereof, and methods of using said compounds and compositions thereof. More specifically, the present disclosure relates to triazolopyrimidine and imidazolopyrimidine inhibitors of ENPP1 and methods of their use for treating disease mediated by ENPP1.
    Type: Grant
    Filed: June 15, 2021
    Date of Patent: September 17, 2024
    Assignee: Volastra Therapeutics, Inc.
    Inventors: Sarah Bettigole, Michael Su, Derek A. Cogan, Leon Van Berkom, Piotr Nieczypor, Gydo Van Der Heijden, Prashanna Vijayachandran
  • Indoline compounds for inhibiting KIF18A
    Patent number: 12084420
    Abstract: The present disclosure relates generally to inhibitors of KIF18A, compositions thereof, and methods of using the compounds and compositions thereof. More specifically, the present disclosure relates to indoline inhibitors of KIF18A and methods of their use for treating disease mediated by KIF18A, such as cancer.
    Type: Grant
    Filed: August 25, 2022
    Date of Patent: September 10, 2024
    Assignee: Volastra Therapeutics, Inc.
    Inventor: Derek A. Cogan
  • COMPOUNDS FOR INHIBITING KIF18A
    Publication number: 20230382889
    Abstract: The present disclosure relates generally to inhibitors of KIF18A, compositions thereof, and methods of using said compounds and compositions thereof. More specifically, the present disclosure relates to inhibitors of KIF18A and methods of their use for treating disease mediated by KIF18A, such as cancer.
    Type: Application
    Filed: April 27, 2023
    Publication date: November 30, 2023
    Applicant: Volastra Therapeutics, Inc.
    Inventor: Derek A. COGAN
  • Imino sulfanone inhibitors of ENPP1
    Patent number: 11780849
    Abstract: The present disclosure relates generally to inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), compositions thereof, and methods of using said compounds and compositions thereof. More specifically, the present disclosure relates to sulfoximine-based inhibitors of ENPP1 and methods of their use for treating disease mediated by ENPP1.
    Type: Grant
    Filed: May 3, 2021
    Date of Patent: October 10, 2023
    Assignee: Volastra Therapeutics, Inc.
    Inventors: Derek A. Cogan, Sarah Bettigole, Leon Van Berkom, Piotr Nieczypor, Michael Su, Rutger Folmer
  • INDOLINE COMPOUNDS FOR INHIBITING KIF18A
    Publication number: 20230147507
    Abstract: The present disclosure relates generally to inhibitors of KIF18A, compositions thereof, and methods of using said compounds and compositions thereof. More specifically, the present disclosure relates to indoline inhibitors of KIF18A and methods of their use for treating disease mediated by KIF18A, such as cancer.
    Type: Application
    Filed: August 25, 2022
    Publication date: May 11, 2023
    Applicant: Volastra Therapeutics, Inc.
    Inventor: Derek A. COGAN
  • HETEROCYCLIC INHIBITORS OF ENPP1
    Publication number: 20230036933
    Abstract: The present disclosure relates generally to inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), compositions thereof, and methods of using said compounds and compositions thereof. More specifically, the present disclosure relates to triazolopyrimidine and imidazolopyrimidine inhibitors of ENPP1 and methods of their use for treating disease mediated by ENPP1.
    Type: Application
    Filed: June 15, 2021
    Publication date: February 2, 2023
    Applicant: Volastra Therapeutics, Inc.
    Inventors: Sarah BETTIGOLE, Michael SU, Derek A. COGAN, Leon VAN BERKOM, Piotr NIECZYPOR, Gydo VAN DER HEIJDEN, Prashanna VIJAYACHANDRAN
  • IMINO SULFANONE INHIBITORS OF ENPP1
    Publication number: 20230002406
    Abstract: The present disclosure relates generally to inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), compositions thereof, and methods of using said compounds and compositions thereof. More specifically, the present disclosure relates to sulfoximine-based inhibitors of ENPP1 and methods of their use for treating disease mediated by ENPP1.
    Type: Application
    Filed: May 3, 2021
    Publication date: January 5, 2023
    Applicant: Volastra Therapeutics, Inc.
    Inventors: Derek A. COGAN, Sarah BETTIGOLE, Leon VAN BERKOM, Piotr NIECZYPOR, Michael SU, Rutger FOLMER
  • Bicyclic imidazole derivatives useful for the treatment of renal diseases, cardiovascular diseases and fibrotic diseases
    Patent number: 10858342
    Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5 and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: December 8, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Michael Balestra, Jennifer Burke, Zhidong Chen, Derek Cogan, John Lord, Daniel Richard Marshall, Bryan P. McKibben, Kenneth M. Meyers, Yunlong Zhang
  • BICYCLIC IMIDAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF RENAL DISEASES, CARDIOVASCULAR DISEASES AND FIBROTIC DISEASES
    Publication number: 20200109131
    Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5 and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: June 21, 2017
    Publication date: April 9, 2020
    Inventors: Michael BALESTRA, Jennifer BURKE, Zhidong CHEN, Derek COGAN, John LORD, Daniel Richard MARSHALL, Bryan P. MCKIBBEN, Kenneth M. MEYERS, Yunlong ZHANG
  • Aldosterone synthase inhibitors
    Patent number: 10131642
    Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein X, R1, R2 and R3 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: November 20, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Michael Balestra, Jörg M. Bentzien, Jennifer Burke, Derek Cogan, Xin Guo, Keith R. Hornberger, John Lord, Kenneth M. Meyers, Zhaoming Xiong, Maolin Yu, Zhonghua Zhang
  • ALDOSTERONE SYNTHASE INHIBITORS
    Publication number: 20180312475
    Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein X, R1, R2 and R3 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: January 28, 2016
    Publication date: November 1, 2018
    Inventors: Michael BALESTRA, Jörg M. BENTZIEN, Jennifer BURKE, Derek COGAN, Xin GUO, Keith R. HORNBERGER, John LORD, Kenneth M. MEYERS, Zhaoming XIONG, Maolin YU, Zhonghua ZHANG
  • Aldosterone synthase inhibitors
    Patent number: 9890171
    Abstract: The present invention relates to compounds of the formulas (IA) and (IB) and pharmaceutically acceptable salts thereof, wherein A and R1-R6, are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: December 1, 2015
    Date of Patent: February 13, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Zhidong Chen, Derek Cogan, Xin Guo, Daniel Richard Marshall, Kenneth Michael Meyers, Yunlong Zhang
  • ALDOSTERONE SYNTHASE INHIBITORS
    Publication number: 20170267688
    Abstract: The present invention relates to compounds of the formulas (IA) and (IB) and pharmaceutically acceptable salts thereof, wherein A and R1-R6, are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: December 1, 2015
    Publication date: September 21, 2017
    Inventors: Zhidong CHEN, Derek COGAN, Xin GUO, Daniel Richard MARSHALL, Kenneth Michael MEYERS, Yunlong ZHANG
  • Aldosterone synthase inhibitors
    Patent number: 9334285
    Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein Cy, R1 and R2 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: July 23, 2015
    Date of Patent: May 10, 2016
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Jennifer Burke, Matthew A. Cerny, Derek Cogan, Kosea S. Frederick, John Lord, Daniel Richard Marshall, Bryan P. McKibben, Simon Suprenant, Maolin Yu, Yunlong Zhang, Lee Fader
  • ALDOSTERONE SYNTHASE INHIBITORS
    Publication number: 20160024105
    Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein Cy, R1 and R2 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: July 23, 2015
    Publication date: January 28, 2016
    Inventors: Jennifer BURKE, Matthew A. CERNY, Derek COGAN, Kosea S. FREDERICK, John LORD, Daniel Richard MARSHALL, Bryan P. MCKIBBEN, Simon SURPRENANT, Maolin YU, Yunlong ZHANG, Lee FADER
  • Aldosterone synthase inhibitors
    Patent number: 9181272
    Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, W, Y, m and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: April 28, 2014
    Date of Patent: November 10, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Michael Balestra, Jennifer Burke, Zhidong Chen, Derek Cogan, Lee Fader, Xin Guo, Bryan McKibben, Daniel Richard Marshall, Peter Allen Nemoto, Hui Yu
  • ALDOSTERONE SYNTHASE INHIBITORS
    Publication number: 20140323468
    Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2. R3, R4, R5, R6, R7, W, Y, m and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: April 28, 2014
    Publication date: October 30, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Michael BALESTRA, Jennifer BURKE, Zhidong CHEN, Derek COGAN, Lee FADER, Xin GUO, Bryan MCKIBBEN, Daniel Richard MARSHALL, Peter Allen NEMOTO, Hui YU
  • Alpha-substituted -sulfonyl gylcine amides antagonists of CCR10, compositions containing the same and methods for using them
    Patent number: 8859814
    Abstract: Disclosed is a compound of formula (I). Wherein R1, R2Ar and Cy are as defined herein, or a pharmaceutically acceptable salt thereof. Also disclosed are pharmaceutical compositions of the compound of formula (I), methods of making the compounds of formula I, and methods of using the compounds of formula (I) to treat a disorder associated with activation of CCR10.
    Type: Grant
    Filed: May 14, 2009
    Date of Patent: October 14, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Derek Cogan, Alexander Heim-Riether, Wang Mao, Craig Andrew Miller, Philip Dean Ramsden, Lana Louise Smith Keenan, Roger John Snow, Jiang-Ping Wu, Yu Yang